Tesamorelin vs. CJC-1295: pulsatility, half-life, and receptor selectivity
Side-by-side pharmacokinetics of GHRH analogs, why plasma half-life doesn't equal downstream IGF-1 exposure, and where the literature disagrees on visceral adiposity endpoints.